Adrian Bebenek

Biotech investor || Harvard Chem Bio || Yale

[FierceBiotech @FierceBiotech]

Johnson & Johnson is paying $3.05 billion to acquire Halda Therapeutics, obtaining a novel cell death platform while strengthening its prostate cancer franchise built on Erleada. $JNJ
https://t.co/4j5WqAGm50

[Cell Chemical Biology @CellChemBiol]

Development of an FKBP12-recruiting chemical-induced proximity DNA-encoded library and its application to discover an autophagy potentiator by Zher Yin Tan, @SchreiberStuart, @TheXavierLab at @broadinstitute https://t.co/OEMtgA60du

[Adrian Bebenek @AdrianBebenek]

@biomiko Gratulacje!

[Jing Liang 🇺🇦 @AppleHelix]

I think this will become much more common going forward. Pharma in-licensing IND-enabled or Phase 1 assets.

Frankly, this is probably the BEST "in-house" R&D strategy

[Xavier Lab @TheXavierLab]

New work out now @CellChemBiol! We developed a non-degrader CIP-DEL platform for discovery of modulators of protein-protein interaction, and identified a compound that blocks caspase 3 cleavage and reverses functional defects of #IBD risk variant ATG16L1 T300A.

[Xavier Lab @TheXavierLab]

(1/5) Excited to share this collab with the Cravatt lab at @scrippsresearch! A structurally diverse library of photoreactive, stereoselective chemical probes can be used for high-throughput #proteomics experiments in living systems.

https://t.co/aZIeLEHIUn

[Vida Ventures @Vida_Ventures]

#CandidTherapeutics, led by Ken Song, launched today with $370M in funding. Vida is proud to support Candid as it develops cutting-edge therapeutic programs that address significant unmet medical needs in immunology. Learn more: https://t.co/CYzSxSqeNO #VidaPortfolio

[Jim Wells @realJimWells]

Big day for the lab as our MultiMap platform is now published on Science! Congratulations to Lindsey @Zhi_Lindsey_Lin and the team! https://t.co/NZYlQRjWD9

[F. Perry Wilson, MD MSCE @fperrywilson]

Well we finally got an Ozempic vs. Mounjaro head-to-head (kind of)... Brief thread to break down the weight-loss-drug showdown...

[Adam Feuerstein ✡️ @adamfeuerstein]

$LLY buyinng $MORF $3.2B - oral integrin for inflammatory bowel disease.

$57 per share. 78% premium.

https://t.co/0WLgshUZ3A

[Xin Wang @XWang829]

Previous papers have shown that drug targets with supporting genetic evidence can have twice the success rate when reaching clinical trials. In our most recent paper (https://t.co/Rq5ZVaOwgj), we looked at how data from @23andMe can provide additional genetic evidence. 🧵1/8

[Jorge Conde @JorgeCondeBio]

Recent draft guidance from @US_FDA on 'platform technology designation' would enable companies to reuse prior data for future approvals.

A small step, a giant leap? We may be entering the 'reusable rocket' era for biotech...
🧬🚀

Draft document: https://t.co/c5pZTRK1UY

[Pharmdca @Pharmdca]

$VKTX

Infact $AMGN discontinuing Oral drug either due to low efficacy or Safety issues is big positive for $VKTX

$AMGN Remember 50% Discontinuation rates,
60-100% Nausea at 280mg dose, 100% nausea at 420mg dose. 83% vomiting at 280mg and 75% vomiting at 420mg dose

Can’t wait for $AMGN data EOY

[Pascal N. Timshel @ptimshel]

Does single-cell data increase probability of success in drug discovery and clinical success? 🧐
Drug targets backed by single-cell data triple the chances of a target reaching phase III, when combined with genetic data 🎯

Read the pre-print of this brilliant study by @sanofi and @sangerinstitute here: https://t.co/C61U0U7keI

@humancellatlas project and single-cell omics promised to transform biology and medicine. This is proof for that promise: a demonstrated and quantified impact of single-cell target analysis on clinical success with clear examples & explanations 🙌

Congratulations to the team behind the study for tackling a research question many of us has been pondering over for years. A prominent example of industry x academic collaboration 💪 @emmamarydann, @teichlab, @VirginiaSavova, @elmentaite and many more.

#DrugDiscovery #TargetDiscovery #SingleCellOmics #RnD

[Rapé Lab @RapeLab]

Congratulations to #MolecularTherapeutics faculty @bignerdzzy and @kevansf on their wonderful paper on targeting the G12D variant of K-Ras!

https://t.co/JMi3IWZBOb

[PHARM.Dabbler @PharmDabbler]

$VKTX obesity market has all the momentum.

Likely suitors:
- $PFE - just pulled their Ph3 trial from Danuglipron twice daily dosing due to AE’s. Wants in obesity market.
- $LLY - could own the obesity market with $VKTX and tirzepatide. Has speculation interest. Approaching $1T market cap soon.
- $MRK - currently studying efinopegdutide. Wants a piece of the pie. Could immediately be a major player with acquisition.

[Adrian Bebenek @AdrianBebenek]

@DanNomura @FrontierMeds Congrats Dan and everyone at Frontier!Super exciting news

[Adrian Bebenek @AdrianBebenek]

@Chemist_Payne It was only a matter of time…

[Vijay Sankaran @bloodgenes]

Wonderful to have our paper, "Inherited blood cancer predisposition through altered transcription elongation", published (open access) in @CellCellPress today!
https://t.co/DCA3Vy6lZL

🧵 (1/n)

[Adrian Bebenek @AdrianBebenek]

Congratulations @SchreiberStuart! I am very excited to see all that comes out of @arenabioworks — a new model for drug discovery is desperately needed!

https://t.co/iIJV7yTNT0